Ovarian cancer is a type of cancer that begins in the ovaries.
It is the 7th most common cancer in women (excluding skin cancer) and the leading cause of death from gynecologic cancer in developed countries.
The 3 histologic types of ovarian cancer are epithelial (primarily seen in women >50 years of age), germ cell (most commonly seen in women <20 years of age) and sex cord stromal (rare and produces steroid hormones).
The median age at the time of diagnosis is 63 years old and >70% present with advanced disease.
Women with platinum-sensitive ovarian cancer with germline BRCA mutations who relapsed after previously receiving ≥2 lines of chemotherapy demonstrated better objective response rates (ORRs) and progression-free survival (PFS) following treatment with olaparib than platinum-based chemotherapy, according to results of the SOLO3* trial.
According to the Singapore Cancer Registry, ovarian cancer was the fifth most frequent cancer among women in Singapore and accounted for 5.4 percent of all female cancers diagnosed between 2011 and 2015, with an increasing incidence rate through the last four decades.
Use of aspirin or NSAIDs after the diagnosis of ovarian cancer appears to improve ovarian cancer-specific survival, according to data from the ongoing Nurses’ Health Study (NHS) and Nurses’ Health Study II (NHSII).
Women who undergo assisted reproductive technology (ART) treatment for infertility appear to have an elevated risk of ovarian cancer, but the lack of long-term association suggests that detection bias as well as parity and cause of infertility may play roles and not ovarian stimulating hormones, according to a study from Denmark.
Matching targeted therapy to genetic alterations in the tumour improved response rate and long-term survival in patients with advanced cancer who underwent molecular profiling compared with patients who were unmatched to therapy, highlighting the role of molecular testing in precision medicine, the IMPACT* study shows.
Indication and demand for genetic testing have increased in recent years, with tests becoming more readily available and affordable, says a leading oncologist at ESMO Asia 2017, highlighting that appreciation of ethical, social, and legal implications of testing and proper test interpretation are important for optimal patient management.
Rucaparib maintenance therapy increases progression-free survival (PFS) in BRCA-mutant recurrent ovarian cancer (OC) by 77 percent, according to late-breaking results from the ARIEL3 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain.
New drug applications approved by US FDA as of 16 - 31 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
There appears to be no convincing evidence to suggest that prediagnosis use of analgesics provides ovarian cancer survival benefit, according to a study, suggesting the need for further investigation with clearer definitions of drug use and data on postdiagnosis use.
Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
Implementation of the collaborative care in a rheumatoid arthritis (RA) clinic has led to improvements in nonbiologic disease-modifying antirheumatic drugs (nb-DMARDs) optimization, adherence to safety recommendations on nb-DMARD monitoring and detection of adverse drug events in RA patients, according to a Singapore study.